Bladder Cancer. Version 3.2020

被引：423

作者：

Flaig, Thomas W. ^{[1
]}

Spiess, Philippe E. ^{[2
]}

Agarwal, Neeraj ^{[3
]}

Bangs, Rick

Boorjian, Stephen A. ^{[4
]}

Buyyounouski, Mark K. ^{[5
]}

Chang, Sam ^{[6
]}

Downs, Tracy M. ^{[7
]}

Efstathiou, Jason A. ^{[8
]}

Friedlander, Terence ^{[9
]}

Greenberg, Richard E. ^{[10
]}

Guru, Khurshid A. ^{[11
]}

Guzzo, Thomas ^{[12
]}

Herr, Harry W. ^{[13
]}

Hoffman-Censits, Jean ^{[14
]}

Hoimes, Christopher ^{[15
,16
]}

Inman, Brant A. ^{[17
]}

Jimbo, Masahito ^{[18
]}

Kader, A. Karim ^{[19
]}

Lele, Subodh M. ^{[20
]}

Michalski, Jeff ^{[21
,22
]}

Montgomery, Jeffrey S. ^{[18
]}

Nandagopal, Lakshminarayanan ^{[23
]}

Pagliaro, Lance C. ^{[4
]}

Pal, Sumanta K. ^{[24
]}

Patterson, Anthony ^{[25
]}

Plimack, Elizabeth R. ^{[10
]}

Pohar, Kamal S. ^{[26
,27
]}

Preston, Mark A. ^{[28
]}

Sexton, Wade J. ^{[2
]}

Siefker-Radtke, Arlene O. ^{[29
]}

Tward, Jonathan ^{[3
]}

Wright, Jonathan L. ^{[30
]}

Gurski, Lisa A. ^{[31
]}

Johnson-Chilla, Alyse ^{[31
]}

机构：

[1] Univ Colorado, Canc Ctr, Boulder, CO 80309 USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[4] Mayo Clin, Canc Ctr, Rochester, MN USA

[5] Stanford Canc Inst, Stanford, CA USA

[6] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[7] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA

[8] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[9] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[10] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[11] Roswell Park Comprehens Canc Ctr, Buffalo, NY USA

[12] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[13] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[14] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[15] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA

[16] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA

[17] Duke Canc Inst, Durham, NC USA

[18] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[19] UC San Diego Moores Canc Ctr, San Diego, CA USA

[20] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[21] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO 63110 USA

[22] Washington Univ, Sch Med, St Louis, MO 14263 USA

[23] UAB, Oneal Comprehens Canc Ctr, Birmingham, AL USA

[24] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA

[25] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA

[26] Ohio State Univ, Comprehens Canc Ctr, James Canc Hosp, Columbus, OH 43210 USA

[27] Ohio State Univ, Comprehens Canc Ctr, Solove Res Inst, Columbus, OH 43210 USA

[28] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[29] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[30] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, 1124 Columbia St, Seattle, WA 98104 USA

[31] Natl Comprehens Canc Network, Ft Washington, MD USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2020年 / 18卷 / 03期

关键词：

BACILLUS-CALMETTE-GUERIN; METASTATIC UROTHELIAL CARCINOMA; TRANSITIONAL-CELL CARCINOMA; PHASE-II TRIAL; BAND IMAGING CYSTOSCOPY; WHITE-LIGHT CYSTOSCOPY; T1 PAPILLARY CARCINOMA; HIGH-RISK TA; HEXAMINOLEVULINATE FLUORESCENCE CYSTOSCOPY; REPEAT TRANSURETHRAL RESECTION;

D O I：

10.6004/jnccn.2020.0011

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non-muscle-invasive urothelial bladder cancer, and treatment of metastatic urothelial bladder cancer because important updates have recently been made to these sections. Some important updates include recommendations for optimal treatment of non-muscleinvasive bladder cancer in the event of a bacillus Calmette-Guerin (BCG) shortage and details about biomarker testing for advanced or metastatic disease. The systemic therapy recommendations for second-line or subsequent therapies have also been revised. Treatment and management of muscle-invasive, nonmetastatic disease is covered in the complete version of the NCCN Guidelines for Bladder Cancer available at NCCN.org . Additional topics covered in the complete version include treatment of nonurothelial histologies and recommendations for nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary carcinoma of the urethra.

引用

页码：329 / 354

页数：26

共 50 条

[21] Patient-derived bladder cancer xenografts as a platform for drug development in bladder cancer.
Pan, Amy Wang
Zhang, Hongyong
Lin, Tzu-Yin
Li, Yuanpei
Li, Tianhong
Keck, James
Tepper, Clifford
Airhart, Susan D.
Liu, Edison T.
Pan, Chong-xian
White, Ralph de Vere
Lam, Kit S.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[22] Occupational risk factors for male bladder cancer.
Zeegers, M
Swaen, G
Kant, Y
Goldbohm, A
van den Brandt, P
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2001, 153 (11) : S265 - S265
[23] Gender differences in the receipt of treatment for bladder cancer.
Datta, G. D.
Neville, B. A.
Datta, N. S.
Earle, C. C.
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2006, 163 (11) : S110 - S110
[24] Photoluminescent nanoconjugates for molecular imaging of bladder cancer.
Liang, Liuen
Care, Andrew
Sunna, Anwar
Campbell, Douglas
Walsh, Bradley
Zvyagin, Andrei
Gillatt, David
Polikarpov, Dmitry
CLINICAL CANCER RESEARCH, 2020, 26 (15) : 60 - 60
[25] BTAK overexpression is associated with aggressive bladder cancer.
Fraizer, GC
Zhou, H
Diaz, M
Joy, C
Lee, I
Reznikoff, C
Liebert, M
Grossman, HB
Sen, S
AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (04) : A126 - A126
[26] Gene expression profiling of superficial bladder cancer.
Bhardwa, JM
Kumar, M
Berney, DM
Martin, J
Cotter, F
Nargund, V
BRITISH JOURNAL OF CANCER, 2003, 88 : S50 - S50
[27] INTERLEUKINES GENES POLIMORPHISM IN PATIENTS WITH BLADDER CANCER.
Leon, Alberto J.
Leon, Victoriano J.
Garcia, Javier
Urrutia, Manuel
HUMAN IMMUNOLOGY, 2012, 73 : 146 - 146
[28] Flavoperidol as a novel therapeutic agent for bladder cancer.
Railkar, Reema
Sanford, Thomas
Krane, Spencer
Li, Q. Quentin
Agarwal, Piyush K.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
[29] Lymphadenectomy for bladder cancer. Current status and controversies
Metzger, T.
Thalmann, G. N.
Zehnder, P.
UROLOGE, 2012, 51 (03): : 310 - +
[30] Social disparities in the diagnosis and management of bladder cancer.
Hasan, Shaakir
Lazarev, Stanislav
Garg, Madhur
Press, Robert H.
Chhabra, Arpit
Choi, Isabelle
Simone, Charles B.
Gorovets, Daniel
Mehta, Keyur J.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

← 1 2 3 4 5 →